Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female
Interventions: DRUG: pegcyte|DRUG: Neulastim
Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company